These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 19996437)

  • 1. Loa loa microfilarial periodicity in ivermectin-treated patients: comparison between those developing and those free of serious adverse events.
    Kamgno J; Pion SD; Mackenzie CD; Thylefors B; Boussinesq M
    Am J Trop Med Hyg; 2009 Dec; 81(6):1056-61. PubMed ID: 19996437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ocular findings after ivermectin treatment of patients with high Loa loa microfilaremia.
    Fobi G; Gardon J; Santiago M; Ngangue D; Gardon-Wendel N; Boussinesq M
    Ophthalmic Epidemiol; 2000 Mar; 7(1):27-39. PubMed ID: 10652169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection.
    Gardon J; Gardon-Wendel N; Demanga-Ngangue ; Kamgno J; Chippaux JP; Boussinesq M
    Lancet; 1997 Jul; 350(9070):18-22. PubMed ID: 9217715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, controlled, double-blind trial with ivermectin on Loa loa microfilaraemia: efficacy of a low dose (approximately 25 microg/kg) versus current standard dose (150 microg/kg).
    Kamgno J; Pion SD; Tejiokem MC; Twum-Danso NA; Thylefors B; Boussinesq M
    Trans R Soc Trop Med Hyg; 2007 Aug; 101(8):777-85. PubMed ID: 17531279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationships between the prevalence and intensity of Loa loa infection in the Central province of Cameroon.
    Boussinesq M; Gardon J; Kamgno J; Pion SD; Gardon-Wendel N; Chippaux JP
    Ann Trop Med Parasitol; 2001 Jul; 95(5):495-507. PubMed ID: 11487371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Release of Loa loa antigens after treatment with ivermectin].
    Chippaux JP; Nkinin SW; Gardon-Wendel N; Ducorps M
    Bull Soc Pathol Exot; 1998; 91(4):297-9. PubMed ID: 9846220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications for annual retesting after a test-and-not-treat strategy for onchocerciasis elimination in areas co-endemic with Loa loa infection: an observational cohort study.
    Pion SD; Nana-Djeunga H; Niamsi-Emalio Y; Chesnais CB; Deléglise H; Mackenzie C; Stolk W; Fletcher DA; Klion AD; Nutman TB; Boussinesq M; Kamgno J
    Lancet Infect Dis; 2020 Jan; 20(1):102-109. PubMed ID: 31676244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A controlled trial to assess the effect of quinine, chloroquine, amodiaquine, and artesunate on Loa loa microfilaremia.
    Kamgno J; Djomo PN; Pion SD; Thylefors B; Boussinesq M
    Am J Trop Med Hyg; 2010 Mar; 82(3):379-85. PubMed ID: 20207860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoietin for treating post-ivermectin Loa-related serious adverse events?
    Boussinesq M; Kamgno J; Pion SD; Mackenzie CD
    Trends Parasitol; 2010 Jan; 26(1):4-5. PubMed ID: 19879192
    [No Abstract]   [Full Text] [Related]  

  • 10. Encephalopathy after ivermectin treatment in a patient infected with Loa loa and Plasmodium spp.
    Kamgno J; Boussinesq M; Labrousse F; Nkegoum B; Thylefors BI; Mackenzie CD
    Am J Trop Med Hyg; 2008 Apr; 78(4):546-51. PubMed ID: 18385346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ivermectin treatment of Loa loa hyper-microfilaraemic baboons (Papio anubis): Assessment of microfilarial load reduction, haematological and biochemical parameters and histopathological changes following treatment.
    Wanji S; Eyong EJ; Tendongfor N; Ngwa CJ; Esuka EN; Kengne-Ouafo AJ; Datchoua-Poutcheu FR; Enyong P; Agnew D; Eversole RR; Hopkins A; Mackenzie CD
    PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005576. PubMed ID: 28686693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of an association between Plasmodium falciparum infection and post-ivermectin Loa-related non-neurologic serious adverse events.
    Fokom-Domgue J; Pion SD; Gounoue R; Akame J; Nguipdop-Djomo P; Twum-Danso NA; Thylefors B; Boussinesq M; Kamgno J
    Am J Trop Med Hyg; 2014 Feb; 90(2):335-8. PubMed ID: 24420781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Test-and-Not-Treat Strategy for Onchocerciasis in Loa loa-Endemic Areas.
    Kamgno J; Pion SD; Chesnais CB; Bakalar MH; D'Ambrosio MV; Mackenzie CD; Nana-Djeunga HC; Gounoue-Kamkumo R; Njitchouang GR; Nwane P; Tchatchueng-Mbouga JB; Wanji S; Stolk WA; Fletcher DA; Klion AD; Nutman TB; Boussinesq M
    N Engl J Med; 2017 Nov; 377(21):2044-2052. PubMed ID: 29116890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure of the microfilarial reservoir of Loa loa in the human host and its implications for monitoring the progr,ammes of Community-Directed Treatment with Ivermectin carried out in Africa.
    Pion DS; Gardon J; Kamgno J; Gardon-Wendel N; Chippaux JP; Boussinesq M
    Parasitology; 2004 Nov; 129(Pt 5):613-26. PubMed ID: 15552406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Secondary effects of the treatment of hypermicrofilaremic loiasis using ivermectin].
    Ducorps M; Gardon-Wendel N; Ranque S; Ndong W; Boussinesq M; Gardon J; Schneider D; Chippaux JP
    Bull Soc Pathol Exot; 1995; 88(3):105-12. PubMed ID: 8555762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of
    Montour J; Lee D; Snider C; Jentes ES; Stauffer W
    Am J Trop Med Hyg; 2017 Dec; 97(6):1833-1835. PubMed ID: 29016308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Nephropathy and filariasis from Loa loa. Apropos of 1 case of adverse reaction to a dose of ivermectin].
    Cruel T; Arborio M; Schill H; Neveux Y; Nedelec G; Chevalier B; Teyssou R; Buisson Y
    Bull Soc Pathol Exot; 1997; 90(3):179-81. PubMed ID: 9410254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human loiasis in a Cameroonian village: a double-blind, placebo-controlled, crossover clinical trial of a three-day albendazole regimen.
    Tabi TE; Befidi-Mengue R; Nutman TB; Horton J; Folefack A; Pensia E; Fualem R; Fogako J; Gwanmesia P; Quakyi I; Leke R
    Am J Trop Med Hyg; 2004 Aug; 71(2):211-5. PubMed ID: 15306713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid assessment method for prevalence and intensity of Loa loa infection.
    Takougang I; Meremikwu M; Wandji S; Yenshu EV; Aripko B; Lamlenn SB; Eka BL; Enyong P; Meli J; Kale O; Remme JH
    Bull World Health Organ; 2002; 80(11):852-8. PubMed ID: 12481206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repurposed automated handheld counter as a point-of-care tool to identify individuals 'at risk' of serious post-ivermectin encephalopathy.
    Bennuru S; Pion SD; Kamgno J; Wanji S; Nutman TB
    PLoS Negl Trop Dis; 2014 Sep; 8(9):e3180. PubMed ID: 25232954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.